05 · Access & Industry
HHS to allow sale of unapproved peptides under review
Licensed pharmacies, physicians, and federal facilities may compound the six substances after an FDA advisory panel reshaped by Secretary Robert F. Kennedy Jr. backed them.

After Secretary Robert F. Kennedy Jr. reshaped an FDA advisory panel that later backed six unapproved peptides, federal officials are pausing enforcement against compounding them.
A Tuesday HHS notice lets licensed pharmacies, physicians, and federal facilities make Semax, MOTS-c, KPV, Epitalon, TB-500, and BPC-157 during ongoing FDA reviews.
Despite FDA scientists finding insufficient evidence of efficacy and HHS noting potential patient risks, the agency cited strong interest in the substances.
Read the full story at The Hill Health Care ↗
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
GLP-1 use for weight loss nearly quadrupled in two years

A 2026 national survey found that 11% of adults reported currently using a GLP-1 medicine for weight loss

GLP-1 medicines joined America's long weight-loss history instead of replacing it
